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Modeling the implications of changes in vascular calcification
in patients on hemodialysis.
Background. The Treat-to-Goal Study found that sevelamer
slowed the progression of coronary calcification in patients on
hemodialysis compared to calcium-based phosphate binders.
To understand the implications of this effect for cardiovascular
events, risk equations are needed.
Methods. Data on 179 patients on hemodialysis treated at
one center in France included biochemical values during the
year prior to study entry, patient characteristics, and cardiovas-
cular events over an average of 4 years. As arterial calcification
was evaluated ultrasonographically and quantified using a 0 to
4 score, an equation relating this to the electron-beam tomog-
raphy (EBT)-based calcification score used in the trial was de-
veloped and applied to all patients. The estimated scores were
then used in survival and Cox proportional hazards analyses of
cardiovascular events in relation to the degree of calcification,
controlling for other characteristics.
Results. Mean age at inclusion was 54 years, dialysis vintage 70
months, average follow-up 49 months; 32% suffered an event.
The calcification score, diabetes, C-reactive protein (CRP), di-
astolic blood pressure, gender, smoking and hypertension are
independent predictors of cardiovascular risk. The resulting
equation indicates that, relative to a calcification score below
400, the risk of an initial event increases 44% for a score of 600,
and more than doubles for a score of 1000.
Conclusion. In the absence of long-term follow-up studies,
these equations permit quantification of the expected long-
term clinical consequences of the impact of various phosphate
binders on vascular calcification. Together with resource use
and cost information, these equations are key inputs for formal
cost-effectiveness analyses.
Patients with end-stage renal disease (ESRD) are at
high risk for cardiovascular disease, particularly coro-
nary and sudden cardiac death. Epidemiologic and clin-
ical studies have shown that damage to large arteries is
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a major contributory factor to this high cardiovascular
morbidity and mortality. These effects are attributable
to both occlusive lesions, mainly atherosclerotic plaques,
and stiffening of arterial walls [1]. The detection and
quantification of calcium are being used in contempo-
rary coronary imaging practice as a marker for the pres-
ence and extent of atherosclerosis. Although controversy
still exists, evidence supporting the independent predic-
tive value of imaging on the basis of electron-beam to-
mography (EBT) has been accumulating in the general
population [2–8].
Calcification develops at two sites in the arterial wall:
the intima and the media. Arterial intima calcification
represents an advanced stage of atherosclerosis and is
associated with the development of plaques and oc-
clusive lesions. Arterial media calcification is observed
with predilection in muscle-type conduit arteries, such as
femoral, tibial, and uterine arteries [9, 10]. While the pre-
cise pathogenesis remains unclear, several factors likely
contribute to the predisposition to widespread calcifi-
cation in ESRD. Some of the risk factors are the clas-
sic ones associated with coronary artery disease in the
general population (e.g., hypertension, diabetes, dyslipi-
demia), whereas others are specific to ESRD patients
[10]. Loss of kidney function, possibly complicated by
metabolic abnormalities associated with the underlying
disease, produces a myriad of physiologic disturbances,
among which is an increasingly disordered calcium and
phosphate metabolism. Calcium homeostasis is regulated
mainly by the parathyroid gland and the kidney, which
removes any excess. With deteriorating renal function,
patients lack the normal route of excretion and excess
calcium is transported into cellular and interstitial com-
partments. Although this process helps serum calcium
levels stay near normal, it predisposes the patient to ex-
traosseous calcification of soft tissues, including vascular
[11]. The net positive imbalance is exacerbated in those
on hemodialysis by calcium absorption from dialysate,
abnormalities in bone buffering and turnover, and inges-
tion of calcium-based phosphate binders to treat hyper-
phosphatemia [12].
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In 1998, sevelamer hydrochloride (RenagelTM), a non-
metal, noncalcium polymer that binds preferentially to
phosphate through ion exchange and hydrogen bonding
in the duodenum, was shown to be safe and effective in
patients on hemodialysis [13]. More recently, sevelamer
has also been shown to attenuate the progression of coro-
nary and aortic calcification, evaluated using EBT, over
1 year relative to calcium-based binders (Treat-to-Goal
Study) [14, 15].
As long-term follow-up data are not yet available, un-
derstanding the implications of this physiologic effect
from a clinical and economic perspective requires predic-
tive equations. Development of such model cannot wait
for the accumulation of follow-up data because treatment
decisions are made today based on current evidence. In
this paper, we present the approach taken to estimate the
clinical impact, specifically, the cardiovascular risk impli-
cations, of the changes in vascular calcification observed
with sevelamer.
METHODS
As no single data source contained all the necessary
data elements, two steps were necessary to build the
link between the extent of vascular calcification on EBT
and cardiovascular risk. Using data from the Treat-To-
Goal Study, an equation was developed to estimate the
EBT score on the basis of readily available patient and
disease characteristics. Next, this equation was applied
to patients in a separate cohort study of cardiovascu-
lar events to predict their EBT score and this value
was included in regression analyses of the cardiovascular
risk.
Estimating EBT score
The Treat-To-Goal Study was a 1-year, open-label, ran-
domized clinical trial comparing sevelamer with calcium-
based phosphate binders in 200 patients on hemodial-
ysis. Apart from the targeted concentrations of serum
phosphorus, calcium, and intact parathyroid hormone
(iPTH), outcomes also included calcification of the
coronary arteries and thoracic aorta using an EBT
score. The study has been described in detail elsewhere
[14, 15].
Data on baseline characteristics of all patients en-
rolled in the Treat-to-Goal Study were obtained. Mul-
tivariate regression analyses were carried out with the
logarithmically transformed EBT score for coronary ar-
teries as the dependent variable (because the distribu-
tion of the EBT scores was quite skewed, the values
were logarithmically transformed to achieve a normal
distribution and permit use of standard parametric sta-
tistical tests). All other baseline variables were consid-
ered, including clinical characteristics, blood chemistries,
blood pressure parameters, and medical history. Since
the model was for prediction, the subset of variables
retained in the final equation was not selected based
solely on statistical significance, but rather on the over-
all predictive quality of the equation, assessed with the
Press statistic [16]. Thus, in addition to variables of clin-
ical significance and those with a strong effect on EBT
scores in univariate analyses, “weaker” variables and in-
teraction terms that did not necessarily achieve statisti-
cal significance were retained if they improved the Press
statistic.
Estimating cardiovascular disease risk
The determinants of cardiovascular risk were exam-
ined in a dataset of patients on hemodialysis treated
at one center in France. It has previously been demon-
strated in a subset of this population that arterial calci-
fication, measured using a semiquantitative 0 to 4 score,
predicts cardiovascular and all-cause mortality [17]. Here,
we expand on that study in several ways: an additional 69
patients are included, cardiovascular morbidity is con-
sidered, and calcium burden is quantified using the pre-
dicted calcification score derived using the Treat-to-Goal
equation.
Study population. All patients treated at the Hoˆpital
F.H. Manhe`s in Fleury-Me´rogis, France, were eligible for
inclusion in the dataset if they had been on hemodialy-
sis for at least 3 months, and had no clinical cardiovas-
cular disease during the 6 months preceding entry. The
first of 179 patients entered in May 1990; recruitment
closed December 2000; and follow-up ended April 30,
2002. Patients who underwent renal transplantation or
moved were censored at the day of transplantation or
departure (N = 34). During follow-up, all patients were
dialyzed by the same standardized technique, as previ-
ously detailed [18].
Data collection. Information compiled from a ques-
tionnaire filled out at entry into the dialysis unit and
from patients’ files included, among others, age, gender,
race, dialysis vintage, body mass index, diabetes, smok-
ing habits, history of cardiovascular disease (i.e., coronary
artery disease, angina pectoris, congestive heart failure,
peripheral vascular disease, or cerebrovascular disease),
use of antihypertensive drugs and calcitriol, and dose of
calcium carbonate expressed in grams of elemental cal-
cium prescribed.
During follow-up, predialysis serum calcium and phos-
phate were determined twice monthly. Serum albumin,
plasma fibrinogen, and C-reactive protein (CRP) were
measured every 3 months, blood lipids and PTH were
measured every 4 months. In this analysis, averages over
up to 1-year preceding study entry were used. Diastolic
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Table 1. Multiple linear regression analysis predicting the logarithmically transformed electron-beam tomography (EBT) score
Variable definition
Variable b (SE) P (units)
Age 0.02 (0.01) 0.013 C Years
Dialysis vintage 0.35 (0.11) 0.002 D >36 months = 1;
≤36 months = −1
Serum calcium 1.42 (0.73) 0.053 C mmol/L
Serum phosphate 0.39 (0.21) 0.061 C mmol/L
Total cholesterol −0.16 (0.10) 0.117 C mmol/L
High-density lipoprotein cholesterol −0.54 (0.30) 0.077 C mmol/L
Cardiovascular disease history −0.70 (0.12) <0.0001 D no = 1; yes = −1
Cardiovascular disease history × age 0.01 (0.01) 0.139 Interaction term
Abbreviations are: C, continuous; D, dichotomous. The model F is 12 (8 df) (P < 0.0001). The R2 equals 0.40
and systolic blood pressure, pulse pressure, heart rate,
and aortic pulse wave velocity (PWV), determined with
transcutaneous Doppler flow recordings and the foot-to-
foot method, were obtained as described previously [18,
19].
Arterial calcification was evaluated ultrasonographi-
cally in the common carotid artery, the abdominal aorta,
the iliofemoral axis, and the legs. Calcification in each re-
gion was quantified as absent (0) or present (1). A score,
ranging from 0 (absence of calcium deposits) to 4 (calci-
fication present in all segments), was obtained by sum-
ming the studied zones, and independently checked by
two observers, with good reproducibility [19]. For each
patient, the EBT calcification score was estimated using
the regression equation derived from the Treat-to-Goal
Study.
The number, timing, and type of all nonfatal cardiovas-
cular events suffered during follow-up were abstracted
from hospital archives of the nephrology, cardiology, and
vascular surgery departments and intensive care unit. The
time and cause of death were obtained from death cer-
tificates, hospital records, and autopsy data reviewed by
one of the authors (G.M.L.).
Statistical analysis. Cardiovascular events were cate-
gorized into congestive heart failure, coronary artery,
cerebrovascular, aortic and peripheral arterial disease.
Kaplan-Meier survival analysis of first events was done
and the association of cardiovascular risk to the calcifica-
tion score and other known risk factors was assessed using
Cox proportional hazards analysis. Stepwise forward se-
lection identified additional determinants (at P < 0.05).
Where necessary, variables were logarithmically trans-
formed to normalize their distribution. Known cardio-
vascular risk factors that were not automatically retained
were reentered into the equation. The proportionality as-
sumption was checked for all variables in the final model.
Kaplan-Meier survival analysis of time to next (fatal or
nonfatal) cardiovascular event was done in sufferers of a
first nonfatal event.
Analyses were performed using SAS System (version
8.0) and JMP (version 4.0.4) (SAS Institute Inc., Cary,
NC, USA).
RESULTS
Estimated EBT calcification scores
The final regression model for the calcification score
is presented in Table 1. Since the aim is to predict EBT
scores, rather than log EBT scores, the predicted scores
need to be transformed back. The appropriate retrans-
formed estimates are obtained by multiplying the expo-
nential of the individual patients’ predicted log EBT score
with a smearing estimator, defined as the average of the
exponentiated residuals, which equals 1.847 [20, 21].
Estimating cardiovascular risk
Study population. The mean age of the 179 patients
at the time of inclusion was 54 years (SD ±17 years)
and dialysis vintage was 70 months (±71 months). Mean
follow-up was 49 months (range 2 to 111 months); 60%
were male, 51% were past or present smokers, 13% had
insulin-dependent diabetes mellitus, 73% received anti-
hypertensive drugs, and 36% had prior cardiovascular
disease (Table 2). A breakdown of the various etiologies
of ESRD in the study population is provided in Table 3.
Thirty-two percent suffered one or more cardiovascu-
lar events during follow-up. Of 58 initial events, 45 were
nonfatal. An additional 47 events occurred subsequently,
19 of which were fatal. Thus, 32 patients died from cardio-
vascular causes and 20 from other causes. The majority of
the 73 nonfatal events were of the coronary or peripheral
arteries (30 and 29, respectively); there were eight cases
of congestive heart failure, four of aortic disease, and two
cerebrovascular events.
Occurrence of cardiovascular events was associated
with age, body mass index, smoking, dialysis vintage, dia-
betes, prior cardiovascular events, pulse pressure, triglyc-
erides, serum phosphate, fibrinogen, CRP, aortic PWV,
and calcification index. A negative association was noted
with diastolic blood pressure, albumin, and PTH.
Figure 1 provides the distribution of predicted calcifi-
cation scores. The mean score was 1262 ± 1432 (range 40
to 6758; median 592) and increased with the number of
arterial sites calcified: from a mean of 355 (median 274)
for patients with 0 sites calcified to a mean score of 2282
Huybrechts et al: Calcification and cardiovascular risk 1535
Table 2. Characteristics of patients at inclusion, overall and by
occurrence of cardiovascular event during follow-up
Cardiovascular event
during follow-up
Overall No Yes
Parameter (N = 179) (N = 121) (N = 58)
Age years 54 ± 17 50 ± 17 62 ± 12
Male % 60 61 57
Caucasian % 85 82 91
Body mass index kg/m2 23.4 ± 4.0 22.9 ± 4.0 24.3 ± 3.7
Smokers % 51 45 64
Dialysis vintage months 70 ± 71 61 ± 64 88 ± 79
Diabetes % 13 7 24
Cardiovascular history % 36 19 71
Antihypertensive 73 71 78
therapy %
Calcitriol % 38 40 33
Systolic blood pressure 148 ± 27 146 ± 25 153 ± 31
mm Hg
Diastolic blood pressure 82 ± 15 84 ± 15 78 ± 14
mm Hg
Mean blood pressure 104 ± 17 104 ± 17 103 ± 17
mm Hga
Pulse pressure mm Hg 67 ± 21 63 ± 17 75 ± 26
Heart rate bpm 71 ± 12 70 ± 11 72 ± 13
Total cholesterol mmol/L 5.1 ± 1.1 5.0 ± 1.1 5.1 ± 1.1
High-density lipoprotein 1.1 ± 0.4 1.1 ± 0.4 1.1 ± 0.4
cholesterol mmol/L
Low-density lipoprotein 3.6 ± 1.0 3.6 ± 1.0 3.7 ± 0.9
cholesterol mmol/Lb
Triglycerides mmol/L 1.8 ± 0.9 1.7 ± 0.8 2.0 ± 1.1
Albumin g/L 40 ± 3 40 ± 3 38 ± 3
Calcium mmol/Lc 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1
Phosphate mmol/L 1.8 ± 0.5 1.8 ± 0.4 2.0 ± 0.5
Parathyroid hormone 303 ± 286 338 ± 305 231 ± 227
pg/mL
Fibrinogen g/L 4.2 ± 1.0 3.9 ± 0.8 4.9 ± 1.0
C-reactive protein mg/L 10.2 ± 10.5 7.6 ± 8.5 15.6 ± 12.2
Aortic pulse wave 11.1 ± 3.1 10.2 ± 2.2 12.9 ± 3.8
velocity m/sec
Calcification score 1262 ± 1432 735 ± 868 2360 ± 1731
For continuous variables, the mean ± SD is provided.
aCalculated as diastolic blood pressure + 1/3 pulse pressure; bDerived using
the Friedewald formula; cNot corrected for albumin.
Table 3. Etiology of end-stage renal disease (ESRD) in the study
population
Proportion
Etiology of patients
Primary glomerulonephritis 28%
Interstitial nephropathies 18%
Polycystic kidney disease 9%
Systemic disease (e.g., lupus nephritis, amyloidosis) 6%
Diabetes 12%
Vascular nephropathy and hypertension 20%
Unknown 7%
(median 1633) for patients with calcifications at all four
regions. Analysis of variance showed a strong overall as-
sociation between the calcification score and the number
of arterial sites calcified (P < 0.0001).
Initial cardiovascular events. The hazard (k) was
shown to be constant over the study period (0.02411 per
100 person-days). The risk (or cumulative incidence) at
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Fig. 1. Predicted calcification score for 179 patients with end-stage re-
nal disease (ESRD) on hemodialysis at the time of inclusion in the
dataset.
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Fig. 2. Kaplan-Meier survival analysis of time to initial cardiovascular
event, overall and by categorized calcification index. Comparison be-
tween curves was highly significant (log-rank v 2 = 88.04, P < 0.0001)
(low calcification score ≤400, medium calcification score 401 to 1000,
high calcification score >1000).
any given time can thus be estimated as 1 − e−kt. The
probability of surviving without an event was lower with
a higher predicted calcification score (Fig. 2). The final
predictive equation from the Cox proportional hazards
analysis is presented in Table 4. In addition to the calcifi-
cation score, diabetes, high CRP levels and low diastolic
blood pressure were included by the automatic stepwise
selection. Gender, smoking, and hypertension (identified
by use of antihypertensive therapy) were forced in. The
equation suggests that for each unit increase in the loga-
rithmically transformed calcification score, the cardiovas-
cular risk is 2.46 times higher, which roughly corresponds
to a 20% higher risk for each 100-unit increase in the
calcification score (Fig. 3).
A patient’s hazard ratio (HRi) can be derived directly
from the Cox proportional hazards model, and the in-
dividual’s risk is estimated as 1 − e−k·HRi·t. The change
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Table 4. Cox-proportional hazards analysis for first fatal or nonfatal cardiovascular event
Variable definition
Variable b Hazard ratio P value (units)
Log (calcification score) 0.90 2.46 <0.0001 C
Diabetes −0.49 0.61 0.0048 D No = 1; yes = −1
Log (C-reactive protein) 0.49 1.64 0.0050 C mg/L
Diastolic blood pressure −0.03 0.97 0.0058 C mm Hg
Gender −0.48 0.62 0.0043 D Male = 1; female = −1
Smoking −0.40 0.67 0.0162 D No = 1; yes = −1
Hypertension −0.40 0.67 0.0142 D No = 1; yes = −1
Abbreviations are: C, continuous; D, dichotomous; Model P < 0.0001; 18% of variance explained.
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Fig. 3. Relative cardiovascular disease risk by calcification score. The
vertical bars indicate the 95% confidence interval. The risk in patients
with a calcification score between 0 and 400 is used as the reference.
Point estimates are provided for the median (∼600), the mean (∼1250),
and the 75% quartile (∼1600) scores estimated for the 179 patients in
the dataset
in cardiovascular risk by calcification score at a popula-
tion level is further illustrated in Figure 4. For this par-
ticular population (60% males, 12% diabetics, 6% smok-
ers, 73% taking antihypertensive therapy, mean CRP 7.8
mg/L, mean diastolic blood pressure 81.5 mm Hg), the
4-year risk equals 4% at a calcification score of 100, and
increases to 13% for a score of 400, 26% for a score
of 1000, and is as high as 72% for a score of 7000—the
maximum calcification score estimated for patients in the
source dataset.
Subsequent cardiovascular events. The hazard of sub-
sequent cardiovascular events followed a Weibull distri-
bution given by:
kt = c
a
(
t
a
)c − 1
where c and a, the scale and shape parameters, were 0.658
and 941.553, respectively. The resulting risk of additional
events immediately following an event is very high (93%
per year), but gradually decreases over time (36% per
year after 6 months, 29% per year after 1 year, and 19%
per year after 4 years) (Fig. 5).
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Fig. 4. Four-year cardiovascular disease (CV) risk by calcification score
for a sample population defined as 60% males, 12% diabetes, 6% smok-
ers, 73% taking antihypertensive therapy, mean C-reactive protein 7.8
mg/L, mean diastolic blood pressure 81.5 mm Hg. This relationship be-
tween calcification score and cardiovascular risk is derived by applying
the hazard ratios estimated for this sample population using the Cox
proportional hazards equation to the constant base hazard
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Fig. 5. Change in hazard over time for subsequent cardiovascular dis-
ease events.
Sevelamer versus calcium-based phosphate binders
Given the findings from the Treat-to-Goal Study and
using these predictive equations, it can now be estimated
that in a population of 100 patients, 33 of those receiv-
ing sevelamer are likely to experience an initial cardio-
vascular event, compared with 37 of those who receive
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calcium. A total of 32 subsequent events are expected to
occur while on sevelamer treatment, compared with 37
on calcium. Sevelamer use, by slowing or reversing coro-
nary calcification as reflected in EBT, is thus estimated to
prevent a total of nine events over the patients’ lifetime,
which represents a 12% reduction in cardiovascular risk.
Therefore, 11 patients would need to be treated for 1 year
to prevent one cardiovascular event.
DISCUSSION
The purpose of this study was to translate the findings
of the Treat-to-Goal Study to clinically meaningful es-
timates. This was done by estimating the EBT score on
the basis of various patient characteristics and then de-
riving the association between this vascular calcification
index and the occurrence of cardiovascular events in pa-
tients on hemodialysis. The equation predicting the EBT
was quite strong as were the multivariate risk calcula-
tions, which suggest that the degree of vascular calcifica-
tion provides incremental prognostic information beyond
gender, smoking, hypertension, diabetes, CRP, and dias-
tolic blood pressure. It may seem surprising that some
known risk factors, such as age, cardiovascular history,
and cholesterol, are not included directly in that Cox pro-
portional hazards equation. It should be noted, however,
that their effect is conveyed through the derived calcifi-
cation score since they are included as independent vari-
ables in the regression equation used to derive that value.
When examined in relative terms, the risk increase ob-
served for scores above 400 (Fig. 3) is more pronounced
than those observed above the 5.5 mg/dL cutoff point for
serum phosphorus levels [22, 23].
These predictive equations permit quantification of the
cardiovascular implications of using sevelamer instead of
calcium-based binders to treat hyperphosphatemia in pa-
tients on hemodialysis. Indeed, based on the findings of
the Treat-To-Goal Study, a 12% decrease in cardiovascu-
lar risk is expected to occur over the patients’ lifetime.
The association between calcification measured by
EBT and clinical coronary artery disease has been docu-
mented in initially asymptomatic, low-to-intermediate-
risk individuals without ESRD [3–7]. For high-risk
individuals, the relationship has been somewhat less clear
[2], although the validity of this study’s conclusions has
been challenged due to the imaging technique used [24].
In patients with ESRD, the association between calcifica-
tion and mortality was shown in a subset of the patients
included in this analysis. In that analysis, both arterial
calcification (measured using the semiquantitative 0 to 4
score) and increased common carotid artery incremen-
tal elastic modulus (a measure of arterial function) were
strongly and independently predictive of mortality [17].
Although the original 0 to 4 score is reproducible, inex-
pensive, and readily available, it is imprecise because, as
discussed in the original paper, it does not quantitate the
calcium concentration in the arteries [17], whereas the
Agatston score derived from an EBT does so with great
sensitivity, which was the rationale for including it as a
measure in the Treat-to-Goal Study [14, 15].
These results should be interpreted in view of several
limitations. First, in the absence of a dataset with both
components (EBT calcification score and cardiovascular
events over time), the EBT scores were derived using a
regression equation rather than being measured directly.
The predicted score adequately discriminated between
patients with high and low EBT scores, however, and a
significant positive association was found with the num-
ber of arterial sites calcified. Second, the risk equation is
based on data from only one center in France.
Although it is desirable to have long-term data to con-
firm the effect of sevelamer on cardiovascular risk, it will
take several years for these to be available. In the mean-
time, administrators must decide whether or not to make
this binder available and individual physicians must make
treatment decisions based on the available evidence. The
predictive equations help inform these decisions by quan-
tifying the expected clinical consequences of the physio-
logic effects obtained in clinical trials. The results suggest
that the choice of phosphate binder has implications for
cardiovascular risk in patients on hemodialysis.
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